阅读说明：本技术 含有机体指印待测样品中降血脂药物的检测方法 (Method for detecting blood fat reducing medicine in sample to be detected containing organism fingerprint ) 是由 张云峰 于 2020-12-31 设计创作，主要内容包括：本发明涉及一种含有机体指印待测样品中降血脂药物的检测方法,包括：采用液相色谱-质谱联用法对待测样品进行测定,根据测定结果中的液相色谱峰保留时间和质谱的子离子和母离子离子强度的比值,确定待测样品中所含降血脂药物；所述降血脂药物包括阿托伐他汀、氟伐他汀、洛伐他汀、普伐他汀、瑞舒伐他汀、辛伐他汀、苯扎贝特、环丙贝特、氯贝特、非诺贝特、依替米贝、吉非罗齐和烟酸,该方法对常见降血脂药物具有较低的检测限,能够实现同时检测多种常见的降血脂药物。(The invention relates to a method for detecting a blood fat reducing drug in a sample to be detected containing organism fingerprints, which comprises the following steps: determining a sample to be detected by adopting a liquid chromatography-mass spectrometry combined method, and determining a blood fat reducing drug contained in the sample to be detected according to the retention time of a liquid chromatography peak in a determination result and the ratio of the ion intensity of a daughter ion and the ion intensity of a mother ion of a mass spectrum; the method has a lower detection limit on common blood fat reducing drugs, and can realize simultaneous detection of multiple common blood fat reducing drugs.)

1. A method for detecting a blood fat reducing drug in a sample to be detected containing body fingerprints is characterized by comprising the following steps:

determining a sample to be detected by adopting a liquid chromatography-mass spectrometry combined method, and determining a blood fat reducing drug contained in the sample to be detected according to the retention time of a liquid chromatography peak in a determination result and the ratio of the ion intensity of a daughter ion and the ion intensity of a mother ion of a mass spectrum;

the hypolipidemic drug comprises atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, bezafibrate, ciprofibrate, clofibrate, fenofibrate, etimibe, gemfibrozil and nicotinic acid.

2. The detection method according to claim 1, further comprising: determining the standard sample of the hypolipidemic drug by adopting the liquid chromatography-mass spectrometry combined method to obtain a standard sample determination result comprising the liquid chromatography peak retention time of each hypolipidemic drug standard sample and the ratio of the ion intensity of the daughter ions and the ion intensity of the parent ions of the mass spectrometry; and comparing the retention time of the liquid chromatographic peak in the measurement result of the sample to be measured and the ratio of the daughter ion intensity and the parent ion intensity of the mass spectrum with the measurement result of the standard sample, and determining the hypolipidemic drug contained in the sample to be measured.

3. The detection method according to claim 1 or 2, further comprising: and recording the peak area of the liquid chromatogram determined according to the sample to be detected, and determining the content of the hypolipidemic drug in the sample to be detected by peak area calculation according to an external standard method.

4. The detection method according to claim 1 or 2, characterized in that the detection method further comprises: and sequentially dissolving and carrying out solid-liquid separation treatment on a sample to be detected to obtain a supernatant, and taking the supernatant as the liquid to be detected measured by the liquid chromatography-mass spectrometry combined method.

5. The detection method according to claim 4, wherein the solvent used for dissolution comprises at least one of methanol and acetonitrile.

6. The detection method according to claim 1, wherein when the determination is performed by using a liquid chromatography-mass spectrometry method, the mobile phase comprises methanol and an aqueous solution containing 0.1% formic acid, and the volume ratio of methanol to the aqueous solution containing 0.1% formic acid is 5: 95; the volume ratio of the methanol to the aqueous solution containing 0.1 percent of formic acid is 35:65 within 1.5-6 min; the volume ratio of the methanol to the aqueous solution containing 0.1 percent of formic acid is 95:5 within 6-8.1 min; for the remainder of the time, the volume ratio of methanol to aqueous solution containing 0.1% formic acid was 5: 95.

7. the detection method according to claim 6, wherein the remaining time is 8.1-11 min.

8. The detection method according to claim 6 or 7, wherein the flow rate of the mobile phase is 0.3 to 0.6 mL/min.

9. The detection method according to claim 6 or 7, wherein the chromatographic column C is used in the measurement by the combination of liquid chromatography and mass spectrometry₁₈The temperature of the chromatographic column is 35-45 ℃.

10. The detection method as claimed in claim 1, wherein the mass spectrometry is performed in a combination of liquid chromatography-mass spectrometry using an s-MRM-IDA-EPI mode, the ion source used in the mass spectrometry is an electrospray ion source, and the ion source temperature is 500-550 ℃.

Technical Field

The invention relates to the technical field of drug detection, in particular to a method for detecting a blood fat reducing drug containing a sample to be detected of body fingerprints.

Background

The common body fluid stains on the scene of the case comprise blood stains, saliva stains, sweat stains, fine stains and the like, and the related information of the person left behind can be obtained by analyzing some life characteristic components in the body fluid stains. Fingerprints are the most common form of sweat spotting in crime scenes and are currently analyzed in a number of ways limited to morphological identification and DNA testing. The fingerprint contains various endogenous and exogenous substances, and relevant information such as biological characteristics, social habits and the like of the legacy persons is contained in the fingerprint. By checking the life characteristic components in the fingerprint, the fingerprint survivors can be carved, thereby providing clues for investigation. This technique is of greater significance when individual identification by fingerprints is not possible.

Hyperlipidemia (hyperlipidemia) generally refers to an increase in plasma triglycerides and/or total cholesterol, and also includes an increase in low density lipoprotein cholesterol and a decrease in high density lipoprotein cholesterol. It is a major factor in atherosclerosis and can also cause cardiovascular and cerebrovascular diseases. The number of patients with hyperlipidemia is large and widely distributed in China, and patients need to take the medicine for a long time, so whether patients have hyperlipidemia diseases or not can be taken as a characteristic of portrayal, and relevant information of fingerprint donors can be obtained by detecting the hypolipidemic medicine in fingerprints. A great deal of literature reports the action mechanism, the metabolic rule and the mutual influence of various hypolipidemic drugs, but the research on the hypolipidemic drugs in fingerprint detection is rarely reported. The method for detecting the common blood fat reducing drugs in the fingerprint is researched and established, the potential information of physical evidence is fully mined to characterize the suspect, a clue can be provided for investigation, and the method has important practical application significance.

At present, the detection methods of the blood fat reducing drugs mainly comprise a spectrum method, an immunity method, a mass spectrometry method, a chromatography method and the like, but because fingerprints are usually small in sample size, the content of the blood fat reducing drugs in a sample containing the fingerprints of an organism is very low, and the existing methods cannot achieve a good detection effect. In order to accurately detect the hypolipidemic drug in the fingerprint, a detection method with a low detection limit needs to be established, and common hypolipidemic drugs in a sample can be simultaneously detected to reduce the sample dosage, which is a technical problem to be solved by the technical personnel in the field.

Disclosure of Invention

The invention aims to provide a method for detecting a blood fat reducing drug in a sample to be detected containing a body fingerprint, which has a lower detection limit and can simultaneously detect a plurality of common blood fat reducing drugs.

The invention provides a method for detecting a blood fat reducing drug in a sample to be detected containing organism fingerprints, which comprises the following steps:

determining a sample to be detected by adopting a liquid chromatography-mass spectrometry combined method, and determining a blood fat reducing drug contained in the sample to be detected according to the retention time of a liquid chromatography peak in a determination result and the ratio (ion-to-abundance ratio) of the ion intensity of a daughter ion and the ion intensity of a mother ion of a mass spectrum; wherein the hypolipidemic drug comprises atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, bezafibrate, ciprofibrate, clofibrate, fenofibrate, etimibe, gemfibrozil and nicotinic acid.

The detection method provided by the invention has lower detection limit and quantitative limit on the 13 common blood fat reducing medicines by using a liquid chromatography-mass spectrometry combined method, can realize accurate qualitative and quantitative detection on the 13 common blood fat reducing medicines, can determine whether the sample to be detected contains the blood fat reducing medicines or not, can determine the specific types of the blood fat reducing medicines contained in the sample to be detected, and can further determine the content of one or more blood fat reducing medicines contained in the sample to be detected, thereby having important practical significance.

In the present invention, the test sample containing the body print may include a permeable object containing the body print. The permeable object is an object capable of allowing sweat stains in body fluid to penetrate into the object, and in the present invention, the permeable object may include various objects having the above permeability characteristics, for example, may include paper having the above permeability characteristics, and specifically may include kraft paper envelopes, newspapers, currency, paper towels, and the like.

The 13 hypolipidemic drugs are all common hypolipidemic drugs and are commercially available, but the invention is not limited to the hypolipidemic drugs, and other hypolipidemic drugs can also be included.

Specifically, each of the above-mentioned hypolipidemic drugs has a specific chromatographic peak retention time and a parent ion/daughter ion pair of the mass spectrum (i.e., a fragment ion (daughter ion) peak generated by further splitting the target molecule ion (parent ion) peak and the parent ion in the mass spectrum, and there may be a plurality of daughter ions, and generally one or two representative daughter ions with the best signal and the highest stability can be selected as the above-mentioned qualitative daughter ion, and the retention time of the liquid chromatographic peak and the ion-to-abundance ratio of the mass spectrum measured according to the sample to be tested can be compared with the retention time of the liquid chromatographic peak of the hypolipidemic drug standard sample and the ion-to-abundance ratio of the mass spectrum to determine whether the sample to be tested contains the above-mentioned hypolipidemic drug or which hypolipidemic drug is contained therein, wherein the chromatographic peak retention time of the hypolipidemic drug standard sample and the ion-to-abundance ratio of the mass spectrum can be obtained by conventional means in the art, the retention time of chromatographic peaks and the ion-to-abundance ratio of mass spectra of the above-mentioned each hypolipidemic drug standard sample can be determined by itself, and the standard sample and the sample to be measured are preferably measured by the same instrument and under the same operating conditions, so as to reduce errors as much as possible.

For example, in a preferred embodiment of the present invention, the detection method further includes: determining the blood fat reducing drug standard samples by adopting the liquid chromatography-mass spectrometry combined method to obtain standard sample determination results comprising the retention time of the liquid chromatogram peak of each blood fat reducing drug standard sample and the ion-to-abundance ratio of the mass spectrum; and comparing the retention time of the liquid chromatographic peak and the ion-to-abundance ratio of the mass spectrum in the determination result of the sample to be determined with the determination result of the standard sample, and determining the hypolipidemic drug contained in the sample to be determined. The liquid chromatogram peak retention time of each hypolipidemic drug standard sample and the ion-to-abundance ratio of the mass spectrum can be sequentially measured, or the hypolipidemic drug standard samples can be mixed and the obtained mixed sample is measured to obtain the standard sample measurement result comprising the liquid chromatogram peak retention time of each hypolipidemic drug standard sample and the ion-to-abundance ratio of the mass spectrum.

Specifically, the determination result of the sample to be determined is compared with the determination result of the standard sample, and if the retention time of a certain liquid-phase chromatographic peak in the determination result of the sample to be determined is substantially consistent with the retention time of a liquid-phase chromatographic peak of a certain lipid-lowering drug standard sample in the determination result of the standard sample, and an ion-to-abundance ratio which is substantially the same as the ion-to-abundance ratio determined according to the lipid-lowering drug standard sample appears, the presence of the lipid-lowering drug in the sample to be determined is determined. Considering factors such as errors existing in the operation process, the relative error between the retention time of a certain liquid-phase chromatographic peak of a sample to be detected and the retention time of a liquid-phase chromatographic peak of a certain standard sample for the hypolipidemic drug is generally within 2.5 percent, and the relative error between the ion-to-ion abundance ratio of the sample to be detected and the degree ratio of the standard sample for the hypolipidemic drug meets the range specified in table 1, so that the sample to be detected can be determined to contain the hypolipidemic drug.

TABLE 1

For example, if a certain liquid chromatography peak retention time T exists in the determination result of the sample to be tested₁Measuring the liquid chromatogram peak retention time T of the atorvastatin standard sample₂，T₂And T₁The relative error of the alpha-atorvastatin standard sample is within +/-2.5%, and meanwhile, the parent ion/daughter ion pairs (after background subtraction) determined according to the alpha-atorvastatin standard sample appear in the determination result of the sample to be determined, and the ion-to-abundance ratio meets the specification of table 1, the alpha-atorvastatin exists in the sample to be determined; if the liquid chromatogram peak retention time T exists in the determination result of the sample to be detected₁、T₃Measuring the liquid chromatogram peak retention time T of the atorvastatin standard sample₂And measuring the liquid chromatogram retention time T of the fluvastatin standard sample₄，T₂And T₁Within. + -. 2.5% of the relative error, T₃And T₄Within ± 2.5% of the relative error, determining that atorvastatin and fluvastatin are present in the sample to be tested.

In one embodiment of the present invention, the measurement results of the standard samples including the liquid chromatographic peak retention time and the parent ion/daughter ion pair of the mass spectrum of each of the hypolipidemic drug standard samples are shown in table 1, and in specific implementation, the liquid chromatographic peak retention time and the parent ion/daughter ion pair of the mass spectrum of the measurement results of the sample to be tested may be compared with the measurement results of the standard samples shown in table 2 to identify the species of the hypolipidemic drug contained in the sample to be tested. For example, if the liquid chromatography peak retention time is 6.47 ± 0.16min and the ion-to-abundance ratio satisfies the range specified in table 1 in the determination result of the sample to be tested, the presence of atorvastatin in the sample to be tested can be determined.

TABLE 2

The present invention may also be applied to a quantitative analysis of the hypolipidemic agent, and in one embodiment of the present invention, the detection method further includes: recording the peak area of the liquid chromatogram according to the sample to be detected, and determining the content of the hypolipidemic drug in the sample to be detected by peak area calculation according to an external standard method.

In specific implementation, the peak area-concentration standard curve of each hypolipidemic drug can be drawn according to the following process: the method can be used for preparing detection solutions containing a certain standard sample of the blood lipid-lowering drug with different concentrations, sequentially measuring the detection solutions with different concentrations by adopting a liquid chromatography-mass spectrometry combination method, obtaining liquid chromatogram peak areas corresponding to the detection solutions, and fitting to generate a standard curve of the liquid chromatogram peak areas and the concentrations of the blood lipid-lowering drug. When the sample to be detected contains a certain blood fat reducing drug, the liquid chromatogram peak area y of the blood fat reducing drug in the determination result of the sample to be detected is obtained, in the standard curve of the peak area and the concentration of the blood fat reducing drug, the concentration corresponding to the liquid chromatogram peak area y is the concentration of the blood fat reducing drug in the liquid to be detected prepared by the sample to be detected, and the concentration of the certain blood fat reducing drug in the sample to be detected can be obtained through conversion.

In an embodiment of the present invention, the detection method further includes: the pretreatment method can more fully extract the hypolipidemic drug contained in the permeable object, namely, the hypolipidemic drug in the sample to be detected enters the supernatant as much as possible, so that the accuracy of the detection process is improved.

The solvent used for dissolving the sample to be tested includes at least one of methanol and acetonitrile, and may be methanol or a mixed solution of methanol and acetonitrile, for example. In a preferred embodiment, the methanol is adopted to dissolve the sample containing the matrix fingerprints, so that the sensitivity of the detection method is improved, and the steps of blow drying, re-dissolving and the like before the sample is tested are omitted, so that the sample is prevented from being polluted better.

In specific implementation, the process of performing dissolution and solid-liquid separation treatment may include: the filter paper collected with the fingerprints can be cut into pieces and placed in a 2ml centrifuge tube filled with 0.5ml of methanol, the centrifuge tube is sequentially subjected to vortex mixing for 1min, ultrasonic oscillation for 3min and centrifugation for 5min (12000r/min), and a supernatant is obtained and is used as a liquid to be detected measured by a liquid chromatography-mass spectrometry combined method. The dissolution and solid-liquid separation treatment is simple, convenient and rapid, and is easy to operate.

According to the research of the invention, when the liquid chromatography-mass spectrometry is used for measurement, the mobile phase can comprise methanol and an aqueous solution containing 0.1% formic acid, and the volume ratio of the methanol to the aqueous solution containing 0.1% formic acid is 5: 95; the volume ratio of the methanol to the aqueous solution containing 0.1 percent of formic acid is 35:65 within 1.5-6 min; the volume ratio of the methanol to the aqueous solution containing 0.1 percent of formic acid is 95:5 within 6-8.1 min; for the remainder of the time, the volume ratio of methanol to aqueous solution containing 0.1% formic acid was 5: 95. the remaining time is generally 8.1-11 min. Through the gradient elution, the hypolipidemic drugs possibly contained in the sample to be detected can be effectively separated.

Wherein the flow rate of the mobile phase is 0.3-0.6 mL/min.

In one embodiment of the present invention, when the measurement is performed by a combination of liquid chromatography and mass spectrometry, C may be used₁₈The column may be, for example, C having an inner diameter of 3mm, a length of 100mm and a filler particle diameter of 1.7. mu.m₁₈The chromatographic column has a column temperature of 35-45 deg.C.

According to the research of the invention, an s-MRM-IDA-EPI (scheduled multiple interaction-dependent acquisition-enhanced production) mode can be adopted in the mass spectrometry process, the mode automatically triggers MS or MS scanning based on a predefined IDA standard on the basis of s-MRM analysis, and the Dynamic Background Subtraction (DBS) function can automatically subtract background ions, so that effective ion information can be obtained while s-MRM quantitative analysis is carried out, and a compound is screened by utilizing the comparison condition of the ion and a spectrum library, thereby being beneficial to improving the detection sensitivity.

According to the research of the invention, the ion source used in the mass spectrometry process can be an electrospray ion source (ESI source), the scanning modes are a positive ion mode and a negative ion mode, and the spray voltage of the positive ion source is 5500V (ESI)⁺) The negative ion source voltage is-4500V (ESI)^-) The ion source Temperature (TEM) may be 500-550 ℃; atomizing gas (GS1) is 55psi, air curtain gas (CUR) is 35psi, auxiliary gas (GS2) is 50psi, and collision gas (CAD) is 7 psi; the injection voltage (EP) of the compound in the positive ion mode is 10V, the injection voltage (CXP) of the collision chamber is 17V, the injection voltage (CXP) of the compound in the negative ion mode is-10V, the injection voltage (CXP) of the collision chamber is-15V, the collision voltage (CE) and the declustering voltage (DP) are optimized to the optimal sensitivity (the maximum response under the detection condition of the invention) before detection, and the optimal collision voltage and declustering voltage corresponding to each hypolipidemic drug are shown in Table 2.

The embodiment of the invention has at least the following beneficial effects:

the technical problem to be solved by the invention is to provide a detection method of a blood fat reducing drug, which has a lower detection limit, can simultaneously detect 13 common blood fat reducing drugs comprising atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, bezafibrate, ciprofibrate, clofibrate, fenofibrate, ezetimibe, gemfibrozil and nicotinic acid, and the detection limit of the 13 blood fat reducing drugs can reach 0.050 ng/patch.

Detailed Description

In order to make the objects, technical solutions and advantages of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.

Example 1 method for testing hypolipidemic agent in fingerprint

In the following experiments, the conditions for measurement by the liquid chromatography-mass spectrometry are as follows, unless otherwise specified:

chromatographic conditions

A chromatographic column: waters ACQUITYBEH C18 (3.0X 100mm Column, 1.7 μm), Column temperature: the mobile phase was methanol (phase B) and 0.1% formic acid in water (phase A) at 40 deg.C, the flow rate was 0.4mL/min, and the gradient elution conditions for each time period are shown in Table 3.

TABLE 3

Time/min	Volume concentration of phase B/% (balance: phase A)
		0.00	5.0
1.00	5.0
		1.50	35.0
6.00	95.0
		8.00	95.0
8.10	5.0
		11.0	5.0

Conditions of Mass Spectrometry

An ion source: electrospray ion source, scanning mode: positive ion mode and negative ion mode, positive ion source spray voltage: 5500V, negative ion source voltage: 4500V, ion source temperature: 550 ℃, atomizing gas: 55psi, air curtain air: 35psi, assist gas: 50psi, collision gas: 7 psi; injection voltage of compound in positive ion mode: 10V, collision cell ejection voltage: 17V; injection voltage of compound in negative ion mode: -10V and-15V for the collision cell ejection voltage.

The scanning mode is as follows: s-MRM-IDA-EPI.

Methanol is used as a solvent, and the following mother liquor with 8 concentrations is prepared: is 2.0. mu.gL^-1、5.0μgL^-1、10.0μgL^-1、20.0μgL^-1、50.0μgL^-1、100.0μgL^-1、200.0μgL^-1、500.0μgL^-1、1000.0μgL^-1And 2000.0. mu.gL^-1(ii) a And preparing detection liquid for each standard sample by using the 8 mother solutions.

(1) Linear test

25 μ L of the mother liquor with the concentration of 8 kinds respectively is taken to prepare 8 groups of mixed standard detection solutions simultaneously containing 13 kinds of the hypolipidemic drugs in the table 2, and the concentration of each hypolipidemic drug in each group of mixed standard detection solutions is the same; the concentrations of the blood fat reducing drugs in the 8 groups of mixed standard detection solutions are respectively as follows: 0.050ng/patch, 0.125ng/patch, 0.250ng/patch, 0.500ng/patch, 1.250ng/patch, 2.500ng/patch, 5.000ng/patch, 12.500ng/patch, 25.000ng/patch, and 50.000 ng/patch.

Sequentially measuring the 8 groups of mixed standard solutions to be measured by adopting a liquid chromatography-mass spectrometry combined method, wherein the sample size is 5 mu L, obtaining liquid chromatogram peak areas corresponding to the various hypolipidemic drug standard samples with different concentrations, performing linear regression by taking the concentration as a horizontal coordinate and the liquid chromatogram peak area as a vertical coordinate, and drawing peak areas-concentration standard samples corresponding to the various hypolipidemic drug standard samplesThe standard curve has the equation shown in Table 4, and the liquid chromatogram peak area corresponding to each standard sample of hypolipidemic drug has a linear relation with the concentration in the range of 0.050-50.000 ng/batch, and the linear correlation coefficient r²All values are greater than 0.99.

TABLE 4

(2) Limit of detection and limit of quantitation determination test

According to the operation procedure of the above (1), a plurality of groups of mixed standard detection solutions containing different concentrations of the respective hypolipidemic drugs are prepared and measured, and the detection limit and the quantification limit of the mixed standard detection solutions are measured, wherein the detection limit and the quantification limit of each drug reach 0.050 ng/batch (S/N >3) and 0.450 ng/batch (S/N > 10).

(3) Precision and accuracy test

Preparing 3 mixed standard detection solutions with the concentrations of 0.250ng/patch, 2.500ng/patch and 25.000ng/patch respectively, sequentially measuring by adopting a liquid chromatography-mass spectrometry combined method, and measuring the daily precision, the daily precision and the daytime precision of the 13 blood fat reducing medicaments in the table 2 as shown in table 5; wherein:

the in-day precision and in-day accuracy of the mixed standard detection solution of each concentration of the hypolipidemic drugs are respectively determined according to the following processes: repeating the measurement for 6 times within 1 day to obtain 6 measured values (i.e. the concentration of each blood lipid lowering drug in the mixed standard detection solution is calculated according to an external standard method), and calculating the relative standard deviation of the 6 measured values, namely the Intra-day precision (Intra-day RSD); the ratio of the average of 6 measurements to the actual value (i.e., the above-mentioned concentration for formulation) was the Intra-day accuracy (Intra-day RSD);

the daytime precision of each concentration of the mixed standard test solution was measured as follows: the measurement was performed once every day for 3 times to obtain 3 measurement values, and the relative standard deviation of the 3 measurement values was calculated as the Inter-day precision (RSD).

TABLE 5

As can be seen from Table 4, the RSD value for day precision does not exceed 11.2%, the accuracy within day is 86.7% -101.0%, and the RSD value for day precision does not exceed 15.1%.

(3) Recovery test

Cutting filter paper with blank fingerprints (organism fingerprints without hypolipidemic drugs) into pieces, placing the pieces into a 2ml centrifugal tube filled with 0.5ml of methanol, and sequentially mixing the pieces in a vortex manner for 1min, carrying out ultrasonic oscillation for 3min and centrifuging for 5min (12000r/min) to obtain blank fingerprint sample supernatant.

3 kinds of mixed standard test solutions containing 13 kinds of hypolipidemic drugs in Table 2 were prepared at concentrations of 0.250ng/patch, 2.500ng/patch and 25.000ng/patch, and the 3 sets of mixed standard test solutions were measured sequentially by the liquid chromatography-mass spectrometry method, and the amount of the sample was 5. mu.L to obtain a measured peak area (C). Adding the mother liquor with proper concentration into the supernatant of the blank fingerprint sample to prepare 3 blank fingerprint sample mixed standard adding solutions to be tested with the same concentration, and sequentially measuring the 3 groups of blank fingerprint sample mixed standard adding solutions to be tested by adopting a liquid chromatography-mass spectrometry combined method, wherein the sample introduction amount is 5 mu L, and thus obtaining a peak area measurement value (A).

The ratio of the peak area measured value (C) of the 3 groups of mixed standard detection solutions to the measured value (A) of the blank fingerprint sample mixed standard addition solution with the same concentration is the recovery rate, and the recovery rate is C/A multiplied by 100%.

The calculated recovery rate is 79.9-114.8%, and the calculation results of the recovery rates of the 13 lipid-lowering drugs are shown in table 6.

TABLE 6

Experimental example:

sample treatment:

finding a fingerprint on a paper towel on a certain scene, cutting off the fingerprint-carrying part of the paper towel, placing the paper towel into a 2ml centrifugal tube filled with 0.5ml of methanol after cutting, and performing vortex mixing on the centrifugal tube for 1min, ultrasonic oscillation for 3min and centrifugation for 5min (12000r/min) in sequence to obtain a supernatant.

The collected fingerprints are measured to contain lovastatin and clofibrate, and the contents of the lovastatin and the clofibrate are respectively 0.205ng/pacth and 0.314 ng/pacth.

The fingerprint is subjected to DNA inspection and warehousing comparison, a fingerprint donor is not found, and the person left with the fingerprint can be judged to be a hyperlipidemic patient according to the fact that the fingerprint contains the 2 lipid-lowering drugs, so that a clue is provided for detection.

Finally, it should be noted that: the above experimental examples are only used to illustrate the technical solution of the present invention, but not to limit the same; although the present invention has been described in detail with reference to the foregoing experimental examples, it will be understood by those skilled in the art that: the technical scheme recorded in each experimental example can be modified, or part or all of the technical features can be equivalently replaced; and the modifications or the substitutions do not make the essence of the corresponding technical scheme depart from the scope of the technical scheme of each experimental example of the invention.